By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Selective immunosuppressants > Omalizumab > Omalizumab Dosage
Selective immunosuppressants
https://themeditary.com/dosage-information/omalizumab-dosage-6259.html

Omalizumab Dosage

Drug Detail:Omalizumab (Omalizumab [ oh-ma-liz-oo-mab ])

Drug Class: Selective immunosuppressants

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

Usual Adult Dose for Asthma - Maintenance

Injectable:
Dose preparation is based on weight and pre-treatment IgE levels:

30 to 60 kg:

  • IgE 30 to 100 international units/mL: 150 mg subcutaneously every 4 weeks
  • IgE 100 to 300 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 300 to 400 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 400 to 600 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE 600 to 700 international units/mL: 375 mg subcutaneously every 2 weeks

60 to 70 kg:
  • IgE 30 to 100 international units/mL: 150 mg subcutaneously every 4 weeks
  • IgE 100 to 200 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 200 to 400 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 400 to 500 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE 500 to 600 international units/mL: 375 mg subcutaneously every 2 weeks
  • IgE greater than 600 international units/mL: Do not dose

70 to 90 kg:
  • IgE 30 to 100 international units/mL: 150 mg subcutaneously every 4 weeks
  • IgE 100 to 200 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 200 to 300 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 300 to 400 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE 400 to 500 international units/mL: 375 mg subcutaneously every 2 weeks
  • IgE greater than 500 international units/mL: Do not dose

90 to 150 kg:
  • IgE 30 to 100 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 100 to 200 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 200 to 300 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE greater than 300 international units/mL: Do not dose

Comments:
  • Interruptions lasting less than 1 year: Dose based on serum IgE levels obtained at the initial dose determination.
  • Interruptions lasting 1 year or more: Retest total serum IgE levels for dose determination.
  • Periodically reassess the need for continued therapy based on the patient's disease severity and level of asthma control.

Use: Management of moderate to severe persistent asthma in patients inadequately controlled with inhaled corticosteroids and with a positive skin test or in vitro reactivity to a perennial aeroallergen

Usual Adult Dose for Urticaria

Injectable: 150 to 300 mg subcutaneously every 4 weeks

Comments:

  • Dosing not dependent on IgE levels or body weight.
  • Avoid administering more than 150 mg per injection site.

Use: Chronic idiopathic urticaria in patients remaining symptomatic after H1 antihistamine treatment

Usual Pediatric Dose for Asthma - Maintenance

Less than 12 years: Not recommended.
12 years and older:
Injectable: Dose preparation is based on weight and pre-treatment IgE levels:

30 to 60 kg:

  • IgE 30 to 100 international units/mL: 150 mg subcutaneously every 4 weeks
  • IgE 100 to 300 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 300 to 400 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 400 to 600 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE 600 to 700 international units/mL: 375 mg subcutaneously every 2 weeks

60 to 70 kg:
  • IgE 30 to 100 international units/mL: 150 mg subcutaneously every 4 weeks
  • IgE 100 to 200 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 200 to 400 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 400 to 500 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE 500 to 600 international units/mL: 375 mg subcutaneously every 2 weeks
  • IgE greater than 600 international units/mL: Do not dose

70 to 90 kg:
  • IgE 30 to 100 international units/mL: 150 mg subcutaneously every 4 weeks
  • IgE 100 to 200 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 200 to 300 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 300 to 400 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE 400 to 500 international units/mL: 375 mg subcutaneously every 2 weeks
  • IgE greater than 500 international units/mL: Do not dose

90 to 150 kg:
  • IgE 30 to 100 international units/mL: 300 mg subcutaneously every 4 weeks
  • IgE 100 to 200 international units/mL: 225 mg subcutaneously every 2 weeks
  • IgE 200 to 300 international units/mL: 300 mg subcutaneously every 2 weeks
  • IgE greater than 300 international units/mL: Do not dose

Comments:
  • Interruptions lasting less than 1 year: Dose based on serum IgE levels obtained at the initial dose determination.
  • Interruptions lasting 1 year or more: Retest total serum IgE levels for dose determination.
  • Periodically reassess the need for continued therapy based upon the patient's disease severity and level of asthma control.

Use: Management of moderate to severe persistent asthma in patients inadequately controlled with inhaled corticosteroids and with a positive skin test or in vitro reactivity to a perennial aeroallergen

Usual Pediatric Dose for Urticaria

Less than 12 years: Not recommended.
12 years and older:
Injectable: 150 to 300 mg subcutaneously every 4 weeks

Comments:

  • Dosing not dependent on IgE levels or body weight.
  • Avoid administering more than 150 mg per injection site.

Use: Chronic idiopathic urticaria in patients remaining symptomatic after H1 antihistamine treatment

Renal Dose Adjustments

Data not available; use with caution.

Liver Dose Adjustments

Data not available; use with caution.

Dose Adjustments

Dose adjustments may be required based on significant changes in weight. The manufacturer product information should be consulted.

Precautions

US BOXED WARNING:

  • ANAPHYLAXIS: Bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat of tongue have been reported in patients administered this drug and may occur beyond 1 year after beginning treatment.
  • Patients should be monitored after administration and anaphylaxis treatments should be available for use in the event of occurrence.
  • Inform patients of signs/symptoms of anaphylaxis and advise them to seek immediate medical care in the event of a reaction.

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Avoid administering more than 150 mg per injection site. Divide doses of greater than 150 mg among at least 2 injection sites.
  • Adjust dosing if patient weight significantly changes.
  • May take 5 to 10 seconds to inject.

Storage requirements:
  • Refrigerate, protect from light.
  • Once reconstituted, use within 8 hours (refrigerated) or 4 hours (room temperature).

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

General:
  • This drug is not indicated for the treatment of acute bronchospasm, status asthmaticus, other forms of urticaria, and other allergic conditions.
  • This drug should be administered by a health care provider experienced in treating severe asthma or chronic spontaneous urticaria.

Monitoring:
  • Retest serum IgE levels for dosing if this drug is interrupted for 1 year or longer
  • Signs and symptoms of anaphylaxis or anaphylactoid reactions
  • Assess asthma control or urticaria symptoms periodically

Patient advice:
  • Do not discontinue current asthma or chronic urticaria therapy when beginning this drug.
  • Instruct patients to notify their healthcare provider upon signs and symptoms of worsening asthma or allergic reaction.
  • Advise patient to speak to healthcare provider if pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

  • What are the most common skin conditions? (with photos)
  • Is Xolair an immunosuppressant?
  • How long before Xolair starts working?
  • How does Xolair work?
  • Does Xolair cause weight gain?
  • What is omalizumab's mechanism of action?
  • Omalizumab and Covid-19 vaccine, what should I know?
  • Can Xolair be self-administered at home?
  • What is Xolair approved for?
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by